Energy expenditure and physical activity in clozapine use: Implications for weight management

Australian and New Zealand Journal of Psychiatry

Volumn 40, Issue 9, 2006, Pages 810-814

  Sharpe, Jenny Kay ^a   Stedman, Terry J ^a   Byrne, Nuala M ^b   Wishart, Connie ^b   Hills, Andrew P ^b  

^a QUEENSLAND CENTRE FOR MENTAL HEALTH RESEARCH   (Australia)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Antipsychotic induced weight gain; Clozapine; Doubly labelled water; Obesity; Schizophrenia

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CITALOPRAM; CLOZAPINE; DIAZEPAM; PAROXETINE; RISPERIDONE; VALPROIC ACID; VENLAFAXINE;

ADULT; ARTICLE; BODY WEIGHT DISORDER; CALORIC INTAKE; CALORIMETRY; CLINICAL ARTICLE; CORRELATION COEFFICIENT; DOUBLY LABELED WATER TECHNIQUE; DRUG USE; ENERGY EXPENDITURE; ENERGY METABOLISM; HUMAN; IMMOBILIZATION; MALE; MENTAL DISEASE; OBESITY; OXYGEN CONSUMPTION; PHYSICAL ACTIVITY; POLYPHARMACY; RISK REDUCTION; SCHIZOPHRENIA; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; ANTIPSYCHOTIC AGENTS; CALORIMETRY, INDIRECT; CLOZAPINE; ENERGY METABOLISM; HUMANS; MALE; MOTOR ACTIVITY; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 33746641002     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1111/j.1440-1614.2006.01888.x     Document Type: Article

References (26)

1. Allison DB, Mentore JL, Heo M et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry 1999; 156:1686-1696.
2. National Institute of Health. Clinical guidelines on the identification, evaluation and treatment of overweight and obesity - the evidence report. Obesity Research 1998; 6:51S-209S.
3. Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophrenia Research 2003; 18:1-7.
4. Allison DB, Mackell JA, McDonnell DD. The impact of weight gain on quality of life among persons with schizophrenia. Psychiatric Services 2003; 54:565-567.
5. Baptista T, Zarate J, Joober R et al. Drug induced weight gain, an impediment to successful pharmacotherapy: Focus on antipsychotics. Current Drug Targets 2004; 5:279-299.
6. Gothelf D, Falk B, Singer P et al. Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. American Journal of Psychiatry 2002; 159:1055-1057.
7. Graham KA, Perkins DO, Edwards LJ, Barrier RC Jr, Lieberman JA, Harp JB. Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. American Journal of Psychiatry 2005; 162:118-123.
8. Schoeller DA. Recent advances from application of doubly labelled water to measurement of human energy expenditure. Journal of Nutrition 1999; 129:1765-1768.
9. Coward WA. The doubly-labelled water (2H218O) method: Principles and practice. Proceedings of the Nutrition Society 1988; 47:209-218.
10. FAO/WHO/UNU. Energy and Protein Requirements. Report of a joint FAO/WHO Ad Hoc Expert Committee. Geneva: Technical Report Series No 724, 1985.
11. Westerterp KR, Meijer EP. Physical activity and parameters of aging: A physiological perspective. Journal of Geronotology Association Series A Biological Sciences and Medical Sciences 2001; 56 (Spec No 2):7-12.
12. Black AE, Coward WA, Cole TJ, Prentice AM. Human energy expenditure in affluent societies: An analysis of 574 doubly-labelled water measurements. European Journal of Clinical Nutrition 1996; 50:72-92.
13. Institute of Medicine of the National Academies. Doubly labeled water data set. [Cited 30 June 2005.] Available from URL: http://www.iom.edu/Object.File/Master/7/302/DGW%20
14. 2 in the obese. Medicine and Science in Sports and Exercise 2002; 34:1419-1427.
15. Weir JB. New methods for calculating metabolic rate with special reference to protein metabolism. Journal of Physiology 1949; 109:1-9.
16. Schoeller DA, Jefford G. Determinants of the energy costs of light activities: Interpreting doubly labelled water. International Journal of Obesity 2002; 26:94-101.
17. World Health Organization. Obesity: Preventing and Managing the Global Epidemic. Report of a WHO consultation. Geneva: WHO Technical Report Series 894, 2000.
18. Wing J, Beevor AS, Curtis RH, Park SBG, Hadden S, Burns A. Health of the Nation Outcomes Scales: Research and development. British Journal of Psychiatry 1998; 172:11-18.
19. Sharpe JK, Byrne NM, Stedman TJ, Hills AP. Resting energy expenditure is lower than predicted in people taking atypical antipsychotic medication. Journal of the American Dietetic Association 2005; 105:612-615.
20. Weinsier RL, Hunter GR, Desmond RA, Byrne NM, Zuckerman PA, Darnell BE. Free-living activity energy expenditure in women successful and unsuccessful at maintaining a normal body weight. American Journal of Clinical Nutrition 2002; 75:499-504.
21. Ravussin E, Lillioja S, Knowler WC. Reduced rate of energy expenditure as a risk factor for body-weight gain. New England Journal of Medicine 1988; 318:467-472.
22. Brar JS, Ganguli R, Padina G, Turkoz I, Berry S, Mahmoud R. Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. Journal of Clinical Psychiatry 2005; 66:205-212.
23. Littrell KH, Hilligoss NM, Kirshner CD, Petty RG, Johnson CG. The effects of an educational intervention on antipsychotic-induced weight gain. Journal of Nursing Scholarship 2003; 35:237-241.
24. Gough S, Peveler R. Diabetes and its prevention: Pragmatic solutions for people with schizophrenia. British Journal of Psychiatry 2004; 184:S112-S14.
25. Ball MP, Coons VB, Buchanan RW. A program for treating olanzapine-related weight gain. Psychiatric Services 2001; 52:967-969.
26. Epstein LH, Valoski AM, Varn LS. Effects of decreasing sedentary behavior and increasing activity on weight change in obese children. Health Psychology 1995; 14:109-115.